Merit Medical (MMSI) Q1 2026 earnings review
Solid Q1 Execution, But M&A Dilution and Tariffs Cap the Outlook
Merit Medical delivered a strong Q1 2026, beating expectations with 7.5% reported revenue growth and expanding non-GAAP operating margins to 19.7%. Under new CEO Martha Aronson, the company is aggressively reshaping its portfolio—divesting the lower-margin DualCap line and acquiring View Point Medical for $140M to bolster its oncology offerings. However, the View Point acquisition will dilute FY26 EPS by $0.05, and mounting tariff costs continue to compress gross margins. While the core business is stable, the guidance implies a deceleration in both top-line and bottom-line growth for the remainder of the year.
🐂 Bull Case
The newly reorganized Therapeutic segment—representing about one-third of total revenue—is driving the top line, growing 10% YoY in Q1. This mix shift supports long-term structural margin improvement.
Free cash flow jumped 26% YoY to $24.7M in Q1. This strong cash generation allows Merit to fund strategic acquisitions like View Point Medical ($90M cash upfront) without over-leveraging the balance sheet.
🐻 Bear Case
Tariffs remain a persistent headwind. Non-GAAP gross margin contracted slightly to 53.2% from 53.4% a year ago. Management previously flagged a $15M FY26 tariff impact, forcing reliance on strict cost controls to grow operating margins.
The $140M View Point Medical acquisition adds just $2-$4M in 2026 revenue while diluting non-GAAP EPS by $0.05, primarily due to lost interest income and transaction expenses.
⚖️ Verdict: ⚪
Neutral. The operational execution is solid and the portfolio shift is strategically sound, but heavy tariff burdens, OEM destocking, and near-term M&A dilution prevent a more bullish outlook.
Key Themes
Strategic Pivot to Therapeutic Products
Merit fundamentally changed its reporting structure in Q1 to highlight its higher-growth engine. The new 'Therapeutic' category grew 10% reported (7% constant currency) to $126.4M, sharply outpacing the 'Foundational' category's 6% growth. This mix shift is accelerating the company's long-term pivot toward high-value disease treatment products.
Macro Headwind: Tariffs Eating Into Gross Margins
Despite aggressive Continuous Growth Initiatives (CGI), macro-driven tariffs are capping profitability. Non-GAAP gross margin declined 20 bps YoY to 53.2%. While management successfully squeezed SG&A to deliver an overall operating margin beat (19.7%), relying purely on operating expense leverage to combat COGS inflation is not a sustainable long-term strategy.
Aggressive Portfolio Pruning and M&A
Management executed two major portfolio moves: shedding the low-margin DualCap line for $28M and buying View Point Medical (OneMark system) for $140M. While the View Point deal expands Merit's therapeutic oncology footprint, the financial math in year one is tough—paying 35x-70x implied 2026 revenue ($2-$4M) for a $0.05 EPS dilution. Execution on integration will dictate if this was a smart long-term play or an overpriced tuck-in.
Foundational Segment Decelerating
The Foundational segment, representing roughly two-thirds of total revenue ($255.5M), is lagging behind the company average. Growing at just 4% on a constant currency basis, this segment is highly exposed to the OEM destocking and China Volume-Based Procurement (VBP) pressures that management cited as severe headwinds in prior quarters. It remains a structural anchor on overall growth.
WRAPSODY and Rhapsody Expectations Reset
After missing original 2025 revenue expectations for the Rhapsody stent, management aggressively reset the baseline. Entering 2026, the guidance assumes highly conservative, low-to-mid-single-digit market penetration (~$7M target). De-risking this narrative allows any acceleration in U.S. adoption to act as an upside surprise rather than a missed promise.
Other KPIs
Accelerating. Up 26% year-over-year from $19.5M in 25Q1. This highlights highly efficient cash conversion despite lower gross margins, giving Merit the liquidity required to close the $90M cash portion of the View Point acquisition without stressing the balance sheet.
Stable. Debt remains completely flat compared to the end of FY25. With $488.1M in cash and cash equivalents, the company has a strong net liquidity position and roughly $697M in available borrowing capacity.
Guidance
Decelerating. The implied 6% to 8% YoY growth is a step down from the 11% constant currency growth delivered in FY25 and the 7.5% achieved in 26Q1. This includes $2-$4M of new revenue from the View Point acquisition, masked partially by the $20M gap left by the DualCap divestiture.
Decelerating. Represents a 5% to 8% YoY growth range, a slowdown compared to the 9.3% growth achieved in Q1. The updated guidance explicitly accounts for a $0.05 dilutive hit from the View Point Medical acquisition, signaling that bottom-line expansion will be harder to achieve for the remainder of the year.
Key Questions
View Point Medical Valuation and Accretion
You paid $140M for a business expected to generate only $2-$4M in revenue for the remainder of the year while diluting EPS by $0.05. What is the specific timeline and margin profile required for this asset to become accretive?
Tariff Mitigation Timeline
With non-GAAP gross margins contracting slightly this quarter, how much of the projected $15M annual tariff headwind has already been absorbed, and when do your supply chain mitigation efforts begin to flow through the P&L?
Foundational Segment Normalization
Your Foundational products grew just 4% on a constant currency basis. Is this purely the result of OEM destocking and China VBP, or are there structural market share losses occurring? When do you expect this segment to normalize?